Read full article here:
The early results of Oxford University and AstraZenecas coronavirus vaccine trial showed robust immune system responses, according to the pharmaceutical firm. COVID-19 vaccine AZD1222 showed robust immune responses in all participants in phase I/II trial, said AstraZenecain an emailed statement. Some 1,077 people took part in the study of AZD1222, which is also known as ChAdOx1 nCoV-19. About half of the participants received the experimental vaccine. UK CORONAVIRUS VACCINE TRIAL IS PROGRESSING VERY WELL, RECRUITING CHILDREN AND OLDER ADULTSIn the research, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. Dr. Adrian Hill, director of the Jenner Institute at Oxford University, said neutralizing antibodies were produced by the vaccine candidate. In addition, the vaccine also causes a reaction in the bodys T-cells, which help to fight off the coronavirus. We are seeing good immune response in almost everybody, said Dr. Hill. What this vaccine does particularly well is trigger both arms of the immune system. Reported side effects from the trial include feeling tired, headaches, muscle aches, chills and fever. No serious side effects were noted. MORE THAN 100 YEARS BEFORE CORONAVIRUS, THE SPANISH FLU PANDEMIC RAVAGED THE GLOBEFurther evaluation of the vaccine is being undertaken. ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses, the researchers wrote, in the study. These results, together with the induction of both humoral and cellular immune responses, support largescale evaluation of this candidate vaccine in an ongoing phase 3 program. The results of the research are published in The Lancet medical journal. With 296,364 cases and 45,385 deaths, the U. K. is one of the most impacted countries by the coronavirus pandemic, according to data compiled by Johns Hopkins
